Trial Profile
An open label, balanced, randomized, two treatment, two-period, two-sequence, crossover, multicentric experimental comparative evaluation of two formulations of Quetiapine extended release tablets 400 mg under fasting conditions after multiple dose administration at steady state in adult schizophrenic patients stabilized on Quetiapine 400 mg per day.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Quetiapine (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Intas Pharmaceuticals
- 02 Oct 2010 Status changed from not yet recruiting to completed as reported by Clinical Trials Registry - India record.
- 09 Feb 2010 New trial record